Lestaurtinib

DB06469InvestigationalSmall molecule

Investigated for use/treatment in pancreatic cancer, prostate cancer, and leukemia (myeloid).

Mechanism: Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3.
Curator reviewed
Primary indication: Investigated for use/treatment in pancreatic cancer, prostate cancer, and leukemia (myeloid).Curator reviewed
Formula / weight: C₂₆H₂₁N₃O₄ · 439.471 g/mol (avg)
Code names: A-154475 · A-154475.0 · CEP-701 · KT-555 · KT-5555 · SP-924 · SPM-924

Resolves to

Compound

Structure

InChIKeyUIARLYUEJFELEN-DMVVYWCZSA-NSMILESC[C@]12O[C@H](C[C@]1(O)CO)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C3C(=O)NC4)C3=CC=CC=C3N21

Targets

What you can answer from here — as of June 15, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

202Drug interactionsStructured to mechanism, not free text

11Clinical trialsPhase, status and sponsor resolved per trial

14+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lestaurtinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.